Stockscreener 앱 받기
1.31
1.55%
0.02
시간 외 거래:
1.31
전일 마감가:
$1.29
열려 있는:
$1.26
하루 거래량:
304.90K
Relative Volume:
1.49
시가총액:
$70.80M
수익:
$76.19M
순이익/손실:
$-1.61M
주가수익비율:
-5.0385
EPS:
-0.26
순현금흐름:
$28.98M
1주 성능:
+0.00%
1개월 성능:
+0.77%
6개월 성능:
-19.63%
1년 성능:
+10.08%
1일 변동 폭
$1.2496
$1.33
1주일 범위
$1.01
$1.33
52주 변동 폭
$1.01
$1.89
Spero Therapeutics Inc Stock (SPRO) Company Profile
명칭
Spero Therapeutics Inc
전화
857-242-1600
주소
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-09-23 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-10-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-22 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-09-29 | 개시 | Evercore ISI | Outperform |
| 2019-11-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-09 | 개시 | Janney | Buy |
| 2018-02-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-11-27 | 개시 | BofA/Merrill | Neutral |
| 2017-11-27 | 개시 | Oppenheimer | Outperform |
| 2017-11-27 | 개시 | Stifel | Buy |
모두보기
Spero Therapeutics Inc 주식(SPRO)의 최신 뉴스
HC Wainwright Cuts Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00 - MarketBeat
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding - Simply Wall St
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Cambridge biotech pulls plug on lung disease drug, cuts 39% of workforce - The Business Journals
Spero Therapeutics to lay off 39% of employees - PharmaLive
Spero Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com South Africa
Spero Therapeutics to Lay Off 39% of Employees - BioSpace
Spero Therapeutics stock hits 52-week low at $1.03 - Investing.com
Spero Therapeutics reports setback in SPR720 study By Investing.com - Investing.com South Africa
Biopharma Co. Escapes Investor Suit Over Drug Approval Lies - Law360
Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program - MarketWatch
Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha
Spero Therapeutics reports setback in SPR720 study - Investing.com India
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - GlobeNewswire
Spero Therapeutics Dodges Investor Suit Over FDA Approval (1) - Bloomberg Law
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - The Manila Times
Spero Therapeutics Announces Presentation of SPR719 (Active - GlobeNewswire
Spero Therapeutics reports promising in vitro NTM treatment data - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Market Insight: Spero Therapeutics Inc (SPRO)’s Notable Drop, Closing at 1.24 - The Dwinnex
An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily
Spero Therapeutics' (SPRO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Spero Therapeutics reports promising Phase 1 trial results for NTM-PD drug - Investing.com
Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy - ForexTV.com
Spero Therapeutics Announces Publication of SPR720 Phase 1 - GlobeNewswire
Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200-Day Moving Average of $1.46 - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200-Day Moving Average of $1.48 - MarketBeat
Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight - PR Newswire UK
Spero Therapeutics Details Pipeline Progress and Future Goals - TipRanks
Spero Therapeutics to Present at Upcoming September Investor Conferences - GlobeNewswire
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200-Day Moving Average of $1.49 - MarketBeat
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200-Day Moving Average of $1.49 - Defense World
Spero Therapeutics COO sells $2,987 in company stock By Investing.com - Investing.com South Africa
Spero Therapeutics CEO sells shares worth over $3.7k By Investing.com - Investing.com Canada
Spero therapeutics director sells shares worth $7,981 - Investing.com India
Spero Therapeutics COO sells $2,987 in company stock - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.49 - Defense World
Spero Therapeutics (STU:2HA) Enterprise Value : €9.12 Mil (As of Aug. 20, 2024) - GuruFocus.com
Spero Therapeutics (STU:2HA) Total Assets : €139.24 Mil (As of Jun. 2024) - GuruFocus.com
Spero Therapeutics (STU:2HA) Debt-to-Revenue : 0.21 (As of Jun. 2024) - GuruFocus.com
Spero Therapeutics (STU:2HA) Financial Strength : 6 (As of Jun. 2024) - GuruFocus.com
SPRO (Spero Therapeutics) Total Liabilities : $69.4 Mil (As of Jun. 2024) - GuruFocus.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Spero Therapeutics Q2 2024 update highlights pipeline progress - Investing.com
Spero Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.38) Per Share, HC Wainwright Forecasts (NASDAQ:SPRO) - MarketBeat
Virtu Financial LLC Purchases New Holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript - Seeking Alpha
HC Wainwright Analysts Reduce Earnings Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World
Spero Therapeutics, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.38) Per Share (NASDAQ:SPRO) - American Banking and Market News
HC Wainwright Weighs in on Spero Therapeutics, Inc.’s Q1 2025 Earnings (NASDAQ:SPRO) - Defense World
Spero Therapeutics Inc (SPRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):